The use of epidermal growth factor receptor (EGFR) inhibitors for the treatment of nonsmall cell lung cancer (NSCLC) commonly triggers cutaneous side effects, which often leads to drug reductions or discontinuation, reports a new study at the recently concluded 2020 Virtual Congress of the European Academy of Dermatology and Venereology (EADV 2020).
The incidence and mortality of pancreatic cancer are on the rise globally, particularly among women and individuals ≥50 years of age, but an increasing trend is also found in younger individuals in some countries.
Adding abemaciclib to adjuvant endocrine therapy (ET) resulted in improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in women with hormone receptor (HR)+, HER2-negative, node-positive early breast cancer at high risk of recurrence, results of the phase III monarchE* trial showed.
A UK study has released further evidence of an increased risk of breast cancer associated with the use of hormone replacement therapy (HRT), with the levels of risk varying among HRT types and becoming higher for combined treatments and longer duration of use.
A faecal immunochemical test (FIT) is able to accurately rule out colorectal cancer (CRC) and is as sensitive as colonoscopy, the current gold standard for CRC diagnosis, the NICE* FIT study has shown.
The initial progression-free survival (PFS) improvement obtained with the addition of olaparib to bevacizumab was sustained beyond first progression, as reflected by the significant PFS2 benefit in women with newly diagnosed, advanced high‐grade ovarian cancer, according to the final PFS2 analysis of the phase III PAOLA-1*/ENGOT-ov25 trial.
The addition of pertuzumab to standard perioperative chemotherapy (CT) comprising FLOT* and trastuzumab led to a significant improvement in pathologic complete response (pCR) in patients with HER2+ resectable oesophagogastric adenocarcinoma – at the expense however of higher toxicity rates, results of the phase II/III PETRARCA/FLOT 6 trial have shown.
In the prespecified, event-driven final analysis of the phase III SPARTAN* trial, adding the androgen receptor inhibitor (ARi) apalutamide to androgen deprivation therapy (ADT) significantly improved overall survival (OS) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).